Keith Regnante - Nov 4, 2023 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Financial Officer
Signature
/s/ Keith Regnante
Stock symbol
KROS
Transactions as of
Nov 4, 2023
Transactions value $
-$1,171,600
Form type
4
Date filed
1/8/2024, 04:43 PM
Previous filing
Jun 12, 2023
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $640K +40K $16.00 40K Nov 4, 2023 Direct F1
transaction KROS Common Stock Sale -$1.81M -40K -100% $45.29 0 Nov 4, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -40K -42.73% $0.00 53.6K Jan 4, 2024 Common Stock 40K $16.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
F2 One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.